Venture Capital

Updated:

Oxonian Ventures

Oxonian Ventures is the leading early-stage venture fund investing in companies founded by Oxford alumni, using investment capital from Oxford alumni and...

Oxonian Ventures logo

Oxonian Ventures

Oxonian Ventures is the leading early-stage venture fund investing in companies founded by Oxford alumni, using investment capital from Oxford alumni and affiliated institutions. It has a portfolio of over 30+ companies and an all-alumni investment team. The firm invests in pre-seed, seed and Series A financings by companies founded by Oxford alumni and is now raising its third fund.

General information

Firm type

Venture Capital

Year founded

2016

Location

Region

North America

Country

United States

City

Palo Alto

Corporate office

380 Hamilton Avenue, Box 854, Palo Alto, CA 94302, United States

Principals

Heather Preston

General Partner

Sector focus

BioTechMedTechFinTechAI/MLSemiconductorsAgriTech & FoodTechClimateTechQuantum ComputingMaterial SciencePrivacyData AnalyticsHRTechEducationAdTechEntertainment Provider

Frequently asked questions

How does Oxonian Ventures source proprietary deal flow?

The firm's sourcing is singular: it invests only in companies founded by University of Oxford alumni. Its capital comes exclusively from accredited investors who also studied at Oxford. This double-sided alumni filter creates an institutionalized warm-introduction network, with founders and investors often surfacing through overlapping university affiliations. The firm does not indicate a cold-outbound or broad market-screening model.

Does Oxonian Ventures participate in fund commitments or only direct deals?

Available information describes only direct early-stage investments into Oxford-alumni-founded operating companies. The firm's website and portfolio pages show no disclosed allocation to external venture funds as a limited partner.

What investment stages does Oxonian Ventures typically target?

The firm targets early-stage and seed-stage companies. Its portfolio includes pre-revenue biotech and quantum computing startups founded as recently as 2024 and 2025, alongside seed-stage fintech and consumer platforms. There is no disclosed allocation to growth equity or later-stage rounds.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on venture capital firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Palo Alto Venture Capital profiles